Short-term lung function changes predict mortality in patients with fibrotic hypersensitivity pneumonitis.
DLCO
FVC
fibrotic hypersensitivity pneumonitis
mortality
predictor
short-term lung function change
Journal
Respirology (Carlton, Vic.)
ISSN: 1440-1843
Titre abrégé: Respirology
Pays: Australia
ID NLM: 9616368
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
revised:
26
11
2021
received:
25
06
2021
accepted:
15
12
2021
pubmed:
14
1
2022
medline:
22
4
2022
entrez:
13
1
2022
Statut:
ppublish
Résumé
A proportion of patients with fibrotic hypersensitivity pneumonitis (fHP) follow a progressive disease course despite immunosuppressive treatment. Little is known about predictors of mortality in fHP. We aimed to investigate the impact of short-term lung function changes in fHP on mortality. Baseline demographics for 145 consecutive patients with a multi-disciplinary team diagnosis of fHP, as well as baseline and 1-year follow-up of lung function, baseline echocardiographic findings, bronchoalveolar lavage (BAL) cellularity and all-cause mortality were recorded. Changes in forced vital capacity (FVC) ≥ 5% and ≥10%, and diffusion capacity of the lung for carbon monoxide (DLCO) ≥ 10% and ≥15% at 1 year were calculated. Cox proportional hazards analysis was performed to test for associations with mortality. Baseline lung function severity, age, presence of honeycombing on computed tomography (CT) and echocardiographic pulmonary arterial systolic pressure (PASP) ≥ 40 mm Hg were associated with early mortality, while BAL lymphocytosis was associated with improved survival. A decline in FVC ≥ 5% (hazard ratio [HR]: 3.10, 95% CI: 2.00-4.81, p < 0.001), FVC ≥ 10% (HR: 3.11, 95% CI: 1.94-4.99, p < 0.001), DLCO ≥ 10% (HR: 2.80, 95% CI: 1.78-4.42, p < 0.001) and DLCO ≥ 15% (HR: 2.92, 95% CI: 1.18-4.72, p < 0.001) at 1 year was associated with markedly reduced survival on univariable and multivariable analyses after correcting for demographic variables, disease severity, honeycombing on CT and treatment, as well as BAL lymphocytosis and PASP ≥ 40 mm Hg on echocardiography, in separate models. Worsening in FVC and DLCO at 1 year, including a marginal decline in FVC ≥ 5% and DLCO ≥ 10%, is predictive of markedly reduced survival in fHP.
Sections du résumé
BACKGROUND AND OBJECTIVE
A proportion of patients with fibrotic hypersensitivity pneumonitis (fHP) follow a progressive disease course despite immunosuppressive treatment. Little is known about predictors of mortality in fHP. We aimed to investigate the impact of short-term lung function changes in fHP on mortality.
METHODS
Baseline demographics for 145 consecutive patients with a multi-disciplinary team diagnosis of fHP, as well as baseline and 1-year follow-up of lung function, baseline echocardiographic findings, bronchoalveolar lavage (BAL) cellularity and all-cause mortality were recorded. Changes in forced vital capacity (FVC) ≥ 5% and ≥10%, and diffusion capacity of the lung for carbon monoxide (DLCO) ≥ 10% and ≥15% at 1 year were calculated. Cox proportional hazards analysis was performed to test for associations with mortality.
RESULTS
Baseline lung function severity, age, presence of honeycombing on computed tomography (CT) and echocardiographic pulmonary arterial systolic pressure (PASP) ≥ 40 mm Hg were associated with early mortality, while BAL lymphocytosis was associated with improved survival. A decline in FVC ≥ 5% (hazard ratio [HR]: 3.10, 95% CI: 2.00-4.81, p < 0.001), FVC ≥ 10% (HR: 3.11, 95% CI: 1.94-4.99, p < 0.001), DLCO ≥ 10% (HR: 2.80, 95% CI: 1.78-4.42, p < 0.001) and DLCO ≥ 15% (HR: 2.92, 95% CI: 1.18-4.72, p < 0.001) at 1 year was associated with markedly reduced survival on univariable and multivariable analyses after correcting for demographic variables, disease severity, honeycombing on CT and treatment, as well as BAL lymphocytosis and PASP ≥ 40 mm Hg on echocardiography, in separate models.
CONCLUSION
Worsening in FVC and DLCO at 1 year, including a marginal decline in FVC ≥ 5% and DLCO ≥ 10%, is predictive of markedly reduced survival in fHP.
Identifiants
pubmed: 35023231
doi: 10.1111/resp.14204
pmc: PMC9302621
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
202-208Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022 The Authors. Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology.
Références
Ann Am Thorac Soc. 2021 Jan;18(1):130-147
pubmed: 32780584
Pulmonology. 2020 May - Jun;26(3):130-137
pubmed: 31672592
Chest. 2013 Aug;144(2):586-592
pubmed: 23392130
Lancet Respir Med. 2013 Nov;1(9):664-5
pubmed: 24429257
Respirology. 2022 Mar;27(3):202-208
pubmed: 35023231
Lancet Respir Med. 2017 Aug;5(8):639-647
pubmed: 28648751
BMC Pulm Med. 2019 Nov 27;19(1):223
pubmed: 31771541
BMC Pulm Med. 2017 May 4;17(1):81
pubmed: 28472939
J Clin Med. 2017 Jun 15;6(6):
pubmed: 28617305
Eur Respir J. 2010 Apr;35(4):830-6
pubmed: 19840957
Chest. 2019 Apr;155(4):699-711
pubmed: 30243979
Respirology. 2017 Nov;22(8):1585-1591
pubmed: 28699237
Chin Med J (Engl). 2019 Jun 5;132(11):1283-1292
pubmed: 31021982
Eur Respir J. 2021 Mar 4;57(3):
pubmed: 33122338
Histopathology. 2012 Dec;61(6):1026-35
pubmed: 22882269
Thorax. 2013 Apr;68(4):309-10
pubmed: 23019257
Clin Exp Immunol. 1991 Nov;86(2):278-85
pubmed: 1934595
Am J Respir Crit Care Med. 2020 Aug 1;202(3):e36-e69
pubmed: 32706311
Chest. 2017 Mar;151(3):619-625
pubmed: 27816444
Pulmonology. 2019 Mar - Apr;25(2):97-108
pubmed: 30126802
Eur Radiol. 2012 Aug;22(8):1672-9
pubmed: 22466512
Life Sci. 2021 May 1;272:119274
pubmed: 33621590
Thorax. 1985 Feb;40(2):138-42
pubmed: 4038823
Eur Respir J. 2020 Apr 23;55(4):
pubmed: 31949120
J Clin Med. 2018 Dec 21;8(1):
pubmed: 30577667
Lancet Respir Med. 2021 May;9(5):476-486
pubmed: 33798455
Thorax. 2018 Apr;73(4):391-392
pubmed: 28883091
Clin Chest Med. 2012 Mar;33(1):165-78
pubmed: 22365253
ERJ Open Res. 2017 Aug 17;3(3):
pubmed: 28845429
Chest. 2013 Nov;144(5):1644-1651
pubmed: 23828161
Am J Respir Crit Care Med. 2003 Apr 1;167(7):962-9
pubmed: 12663338
N Engl J Med. 2019 Oct 31;381(18):1718-1727
pubmed: 31566307